Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 701–800 of 1,012
Grossauer, S., Koeck, K., Murphy, N. E., Meyers, I. D., Daynac, M., Truffaux, N., Truong, A. Y.-Q., Nicolaides, T. P., McMahon, M., Berger, M. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12419 · Cited by 41
Mutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 44
Tumor-Agnostic Drug Development
Offin, M. D., Liu, D., & Drilon, A. E. D. C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200831 · Cited by 44
IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells
Notarangelo, T., Sisinni, L., Trino, S., Calice, G., Simeon, V., & Landriscina, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.038 · Cited by 41
Ma, Y., Zhu, J., Chen, S., Li, T., Ma, J., Guo, S., Hu, J., Yue, T., Zhang, J., Wang, P., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0599-7 · Cited by 43
Capdevila, J., Arqués, O., Hernández Mora, J. R., Matito, J., Caratù, G., Mancuso, F. M., Landolfi, S., Barriuso, J., Jimenez-Fonseca, P., Lopez Lopez, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1266 · Cited by 39
Tumor-Agnostic Treatment for Cancer: When How is Better than Where
Lavacchi, D., Roviello, G., & D’Angelo, A. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00915-5 · Cited by 43
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 44
Krakstad, C., Birkeland, E., Seidel, D., Kusonmano, K., Petersen, K., Mjøs, S., Høivik, E. A., Wik, E., Halle, M. K., Oyan, A. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052795 · Cited by 47
Fisher, K. E., Jani, J. C., Fisher, S. B., Foulks, C., Hill, C. E., Weber, C. J., Cohen, C., & Sharma, J. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.003 · Cited by 42
Zhao, Z., He, J., Qiu, S., Wang, L., Huangfu, S., Hu, Y., Wu, Q., Yang, Y., Li, X., Huang, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58992-z · Cited by 43
Resistance to Raf inhibition in cancer
Haarberg, H. E., & Smalley, K. S. M. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.12.004 · Cited by 44
Microenvironment-mediated resistance to anticancer therapies
Olson, O. C., & Joyce, J. A. (2012) · Cell Research · doi:10.1038/cr.2012.123 · Cited by 47
The next steps in next-gen sequencing of cancer genomes
Hayes, D. N., & Kim, W. Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci68339 · Cited by 41
MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
Asmussen, J. K., Lasater, E. A., Tajon, C. A., Osés-Prieto, J. A., Jun, Y., Taylor, B. S., Burlingame, A. L., Craik, C. S., & Shah, N. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0235 · Cited by 46
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
Zhang, J., Yao, T.-W., Hashizume, R., Hariono, S., Barkovich, K. J., Fan, Q., Prados, M. D., James, C. D., Weiss, W. A., & Nicolaides, T. P. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2333-4 · Cited by 43
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 46
Notarangelo, T., Sisinni, L., Condelli, V., & Landriscina, M. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0457-z · Cited by 41
Implementation of “clinical sequencing” in cancer genome medicine in Japan
Kohno, T. (2017) · Cancer Science · doi:10.1111/cas.13486 · Cited by 43
Palit, S. A. L., Vis, D. J., Stelloo, S., Lieftink, C., Preković, S., Bekers, E. M., Hofland, I., Šuštić, T., Wolters, L., Beijersbergen, R. L., et al. (2019) · eLife · doi:10.7554/elife.47430 · Cited by 40
Self-citationVétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., Bernard, A.-C., Campone, M., Guette, C., & Coqueret, O. (2015) · Oncotarget · doi:10.18632/oncotarget.6126 · Cited by 36
Sato, K., Shin, M., Sakimura, A., Zhou, Y., Tanaka, T., Kawanishi, M., Kawasaki, Y., Yokoyama, S., Koizumi, K., Saiki, I., et al. (2013) · Cancer Science · doi:10.1111/cas.12225 · Cited by 40
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
Self-citationThe MAPK pathway as an apoptosis enhancer in melanoma
Haydn, J. M., Hufnagel, A., Grimm, J., Maurus, K., Schartl, M., & Meierjohann, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2079 · Cited by 45
Prasetyanti, P. R., Capone, E., Barcaroli, D., D’Agostino, D., Volpe, S., Benfante, A., van Hooff, S. R., Iacobelli, V., Rossi, C., Iacobelli, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4642 · Cited by 42
Kim, B., Wang, S., Lee, J. M., Jeong, Y., Ahn, T., Son, D.-S., Park, H. W., Yoo, H.-S., Song, Y.-J., Lee, E., et al. (2014) · Oncogene · doi:10.1038/onc.2014.51 · Cited by 41
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy
Murcia, Ó., Juárez, M., Hernández‐Illán, E., Egoavil, C. M., Giner-Calabuig, M., Soler, M. R., & Jover, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i13.3516 · Cited by 46
Tosi, D., Pérez-Gracia, E., Atis, S., Vié, N., Combès, E., Gabanou, M., Larbouret, C., Jarlier, M., Mollévi, C., Torro, A., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4712-z · Cited by 43
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers
Hofmann, M.-C. C., Kunnimalaiyaan, M., Wang, J. R., Busaidy, N. L., Sherman, S. I., Lai, S. Y., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0129 · Cited by 53
Cheng, H., Chang, Y., Zhang, L., Luo, J., Tu, Z., Lu, X., Zhang, Q., Lu, J., Ren, X., & Ding, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500007h · Cited by 41
Dasgupta, T., & Haas-Kogan, D. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00110 · Cited by 40
A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation
Yan, Y., Hein, A. L., Greer, P. M., Wang, Z., Kolb, R. H., Batra, S. K., & Cowan, K. H. (2014) · Oncogene · doi:10.1038/onc.2014.167 · Cited by 40
An Update on Colorectal Cancer
Xue, L., Williamson, A. J., Gaines, S., Andolfi, C., Paul-Olson, T., Neerukonda, A. R., Steinhagen, E. F., Smith, R. K., Cannon, L. M., Polite, B. N., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.02.003 · Cited by 42
Dienstmann, R., Salazar, R., & Tabernero, J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.91 · Cited by 38
Self-citationIzar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 40
Kim, S. S., Carvajal, R. D., Kim, M., & Yang, H. W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112570 · Cited by 38
Clinical cancer research: the past, present and the future
DeVita, V. T., Eggermont, A. M. M., Hellmän, S., & Kerr, D. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.153 · Cited by 40
Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
Klinac, D., Gray, E. S., Millward, M. J., & Ziman, M. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00054 · Cited by 44
BRAF inhibitors in clinical oncology
Morris, V. K., & Kopetz, S. (2013) · F1000Prime Reports · doi:10.12703/p5-11 · Cited by 39
Wang, V. E. H., Grandis, J. R., & Ko, A. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0292 · Cited by 38
BRAF-Directed Therapy in Metastatic Colorectal Cancer
Korphaisarn, K., & Kopetz, S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000189 · Cited by 39
Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer
Cronise, K. E., Hernandez, B. G., Gustafson, D. L., & Duval, D. L. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115808 · Cited by 39
Su, D., Zhang, D., Jin, J., Ying, L., Han, M., Chen, K., Li, B., Wu, J., Xie, Z., Zhang, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12846-7 · Cited by 41
Ali, E. M. H., Abdel‐Maksoud, M. S., Ammar, U. M., Mersal, K. I., Yoo, K. H., Jooryeong, P., & Oh, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104508 · Cited by 40
Neighbor communities in drug combination networks characterize synergistic effect
Zou, J., Ji, P., Zhao, Y., Li, L., Wei, Y.-Q., Chen, Y., & Yang, S. (2012) · Molecular BioSystems · doi:10.1039/c2mb25267h · Cited by 41
Tie, J., & Desai, J. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0330-0 · Cited by 39
BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
Margalef, P., Colomer, C., Villanueva, A., Montagut, C. O., Iglesias, M., Bellosillo, B., Salazar, R., Martínez‐Iniesta, M., Bigas, A., & Espinosa, L. (2015) · Science Signaling · doi:10.1126/scisignal.2005886 · Cited by 39
Self-citationGarbe, C., Abusaif, S., & Eigentler, T. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_13 · Cited by 38
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 41
Self-citationMolecular alterations in indolent, aggressive and recurrent ovarian low‐grade serous carcinoma
McIntyre, J. B., Rambau, P., Chan, A. M. Y., Yap, S., Morris, D. G., Nelson, G. S., & Köbel, M. (2016) · Histopathology · doi:10.1111/his.13071 · Cited by 37
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 39
Aronchik, I., Dai, Y., Labenski, M., Barnes, C., Jones, T., Qiao, L., Beebe, L., Malek, M., Elis, W., Shi, T., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0554 · Cited by 38
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 38
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 52
Nguyen, L. C., Naulaerts, S., Bomane, A., Bruna, A., Ghislat, G., & Ballester, P. J. (2021) · Biomedicines · doi:10.3390/biomedicines9101319 · Cited by 41
Al-Wahaibi, L. H., Abou‐Zied, H. A., Beshr, E. A. M., Youssif, B. G. M., Hayallah, A. M., & Abdel-Aziz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109104 · Cited by 41
Cooperation between Noncanonical Ras Network Mutations
Stites, E. C., Trampont, P. C., Haney, L. B., Walk, S. F., & Ravichandran, K. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.035 · Cited by 34
“Undruggable KRAS”: druggable after all
Cox, A. D., & Der, C. J. (2024) · Genes & Development · doi:10.1101/gad.352081.124 · Cited by 61
Koumaki, K., Kontogianni, G., Kosmidou, V., Pahitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O., & Pintzas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166061 · Cited by 36
Huijberts, S. C. F. A., Boelens, M. C., Bernards, R., & Opdam, F. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01147-2 · Cited by 36
Self-citationMajumder, A. (2023) · Cells · doi:10.3390/cells12212517 · Cited by 39
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Schäffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E., & Lee, J. S. (2024) · Med · doi:10.1016/j.medj.2023.12.009 · Cited by 40
Modeling Signaling Networks to Advance New Cancer Therapies
Sáez-Rodríguez, J., MacNamara, A., & Cook, S. J. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104927 · Cited by 41
The role of protein tyrosine phosphatases in colorectal cancer
Hoekstra, E., Peppelenbosch, M. P., & Fuhler, G. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.04.001 · Cited by 37
Déjà Vu: EGF Receptors Drive Resistance to BRAF Inhibitors
Girotti, M. R., & Marais, R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0131 · Cited by 39
Jesinghaus, M., Pfarr, N., Endris, V., Kloor, M., Volckmar, A., Brandt, R., Herpel, E., Muckenhuber, A., Lasitschka, F., Schirmacher, P., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22352 · Cited by 38
Konda, J. D., Olivero, M., Musiani, D., Lamba, S., & Renzo, M. F. D. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12042 · Cited by 38
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 39
RoBoT: a robust Bayesian hypothesis testing method for basket trials
Zhou, T., & Ji, Y. (2020) · Biostatistics · doi:10.1093/biostatistics/kxaa005 · Cited by 36
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
Integrating genomics in head and neck cancer treatment: Promises and pitfalls
Thariat, J., Vignot, S., Lapierre, A., Falk, A. T., Guigay, J., Obberghen‐Schilling, E. V., & Milano, G. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.005 · Cited by 41
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Bidshahri, R., Attali, D., Fakhfakh, K., McNeil, K., Karsan, A., Won, J., Wolber, R. A., Bryan, J., Hughesman, C. B., & Haynes, C. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.09.003 · Cited by 41
Perimenis, P., Galaris, A., Voulgari, A., Margarita, P., & Pintzas, A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2606-5 · Cited by 40
Looking beyond drivers and passengers in cancer genome sequencing data
De, S., & Ganesan, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw677 · Cited by 38
Yang, J., Xu, W. W., Hong, P., Ye, F., Huang, X., Hu, H., Zhang, Q., Yan, X., Li, B., & He, Q. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.050 · Cited by 36
Ibrahim, I. A. A., Alzahrani, A. R., Alanazi, I. M., Shahzad, N., Shahid, I., Falemban, A. H., Azlina, M. F. N., & Arulselvan, P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126581 · Cited by 37
Bridging Discovery and Treatment: Cancer Biomarker
Liu, H., Karsidag, I., Golin, R., & Wu, G. (2025) · Cancers · doi:10.3390/cancers17223720 · Cited by 42
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
Hanly, E. K., Bednarczyk, R. B., Tuli, N. Y., Moscatello, A. L., Halicka, H. D., Li, J., Geliebter, J., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4052 · Cited by 37
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Moorcraft, S. Y., Smyth, E. C., & Cunningham, D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13491797 · Cited by 40
In vivo shRNA screens in solid tumors
Gargiulo, G., Serresi, M., Cesaroni, M., Hulsman, D., & van Lohuizen, M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.185 · Cited by 35
Exploiting synthetic lethality to improve cancer therapy
Brunen, D., & Bernards, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.46 · Cited by 36
Self-citationMartinelli, E., Troiani, T., Sforza, V., Martini, G., Cardone, C., Vitiello, P., Ciardiello, D., Rachiglio, A., Normanno, N., Sartore-Bianchi, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000299 · Cited by 34
Self-citationMolecular screening to select therapy for advanced cancer?
Tannock, I. F., & Hickman, J. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz088 · Cited by 36
ERK/MAPK signaling is essential for intestinal development through Wnt pathway modulation
Wei, G., Gao, N., Chen, J., Fan, L., Zeng, Z., Gao, G., Li, L., Fang, G., Hu, K., Pang, X., et al. (2020) · Development · doi:10.1242/dev.185678 · Cited by 39
Zhao, Y., Zhang, B., Ma, Y., Zhao, F., Chen, J., Wang, B., Jin, H., Zhou, F., Guan, J., Zhao, Q., et al. (2022) · Advanced Science · doi:10.1002/advs.202201539 · Cited by 37
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1
Voena, C., Giacomo, F. D., Panizza, E., D’Amico, L., Boccalatte, F. E., Pellegrino, E., Todaro, M., Recupero, D., Tabbò, F., Ambrogio, C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.7 · Cited by 39
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 37
Lung cancer biomarkers, targeted therapies and clinical assays.
Patel, J. N., Ersek, J. L., & Kim, E. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.02 · Cited by 41
BRAF — A new player in hematological neoplasms
Machnicki, M. M., & Stokłosa, T. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.01.001 · Cited by 34
New and emerging factors in tumorigenesis: an overview
Kim, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s47797 · Cited by 43
Schiefer, A., Parlow, L., Gabler, L., Mesteri, I., Koperek, O., von Deimling, A., Streubel, B., Preusser, M., Lehmann, A., Kellner, U., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.12.005 · Cited by 34
Sparidans, R. W., Rosing, H., Rood, J. J. M., Schellens, J. H. M., & Beijnen, J. H. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.09.012 · Cited by 34
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 37
NRF2 Enables EGFR Signaling in Melanoma Cells
Kreß, J. K. C., Jessen, C., Marquardt, A., Hufnagel, A., & Meierjohann, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083803 · Cited by 34
Identifying Novel Actionable Targets in Colon Cancer
Cerrito, M. G., & Grassilli, E. (2021) · Biomedicines · doi:10.3390/biomedicines9050579 · Cited by 36
Autophagy Inhibition in BRAF-Driven Cancers
Foth, M., & McMahon, M. (2021) · Cancers · doi:10.3390/cancers13143498 · Cited by 34
Kavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 37
Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary
Tan, D. S. W., Montoya, J., Ng, Q., Chan, K.-S., Oon, L. L. E., Krisna, S. S., Takano, A. M., Lim, W., Tan, E.-H., & Lim, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3937 · Cited by 36
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.